Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ainovirine + emtricitabine + tenofovir alafenamide fumarate
- Development stage
- Unknown
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ADC118 (also known as ACC118 or by the brand name Ainuotai) is a fixed-dose combination (FDC) antiretroviral therapy developed by Jiangsu Aidea Pharmaceutical for the treatment of HIV-1 infection. It is the first triple-combination single-tablet regimen (STR) containing a domestically developed innovative drug (ainovirine) to be approved in China. The regimen consists of ainovirine (ACC017), a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), combined with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), emtricitabine and tenofovir alafenamide fumarate (TAF). Ainovirine provides potent antiviral activity with a high genetic barrier to resistance and a superior safety profile, particularly regarding central nervous system and liver toxicity, compared to older NNRTIs like efavirenz. The FDC simplifies treatment to a once-daily single tablet, enhancing patient adherence and providing a complete antiretroviral regimen.
- Brand names
- Ainuotai
- Other names
- ainovirine/emtricitabine/tenofovir alafenamide fumarate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on ainovirine + emtricitabine + tenofovir alafenamide fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ainovirine + emtricitabine + tenofovir alafenamide fumarate.